Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05744479
Other study ID # 024/2022
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date February 28, 2023
Est. completion date December 1, 2026

Study information

Verified date February 2023
Source Centre for Addiction and Mental Health
Contact Mahavir Agarwal, MD, PhD
Phone 4165358501
Email mahavir.agarwal@camh.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

People with IDD (intellectual and developmental disability) have very high rates of obesity and die prematurely from cardiometabolic disease. While antipsychotics contribute to this problem, their use is necessary and appropriate in a significant subgroup of individuals with IDD. Exercise and diet interventions have limitations and may not be sufficient, requiring effective adjunctive pharmacological approaches to target obesity and related comorbidities in IDD. However, persons with IDD treated with antipsychotics are systematically excluded from clinical trials hindering development of evidence to help guide safe and effective treatment of these comorbidities. Moreover, evidence from other disorders cannot be extrapolated to IDD given inherent biological differences between disorders. This trial will address the identified gaps, which extend beyond cardiovascular morbidity and negatively impact psychosocial outcomes, in a hugely underserviced population.This is the the first RCT (randomized control trial) to examine the efficacy of metformin in overweight or obese adults with IDD who have experienced antipsychotic-induced weight gain. By generating efficacy data for a very accessible and scalable intervention, allows for guideline and implementation strategies to address a recalcitrant health problem.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 1, 2026
Est. primary completion date December 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Stable outpatients - Age 18-65 years - Diagnosed with IDD - On maintenance treatment with an antipsychotic (stable dose for =3 months). - BMI must be =30 kg/m2, or =27 kg/m2 with at least one weight-related comorbidity (treated or untreated) such as: hypertension, dyslipidaemia, obstructive sleep apnea, or impaired fasting glucose. - Females of child-bearing age must be on one of the following regular contraceptives: 1. Agree to abstain from sex for the duration of the trial or 2. A barrier method of a diaphragm with spermicide and/or Latex condom or 3. An oral contraceptive agent, implantable contraceptive or an injectable contraceptive for at least six months prior to entering the study and will continue its use throughout the study, or 4. An intrauterine device, or 5. Partner has had a vasectomy at least 3 months prior to study start Exclusion Criteria: - Females who are nursing, currently pregnant, or have a positive pregnancy test - Clinical or laboratory evidence of uncompensated cardiovascular, endocrine, haematological, hepatic, renal, or pulmonary disease - Previous treatment and lack of efficacy or tolerability with metformin - History or diagnosis of Type 1 Diabetes (T1D) or Type 2 Diabetes (TD2) or fasting blood work, HbA1c > 6.5% - History of metabolic acidosis or lactic acidosis - Treatment with weight-lowering agents - Medications with significant renal impact - Major medical or surgical event in the preceding 3 months - Acute suicidal risk. - Moderate to severe substance use disorder, other than caffein or nicotine use disorder

Study Design


Intervention

Drug:
Metformin
Metformin oral, 2000mg/day, for 24 weeks.
Placebo
Oral placebo for 24 weeks
Behavioral:
Lifestyle Intervention
Participants from both groups will meet a dietician and a diabetes educator at the study start to obtain advice regarding healthy diet, portion size, and meal planning to improve physical health. All participants will be invited to monthly group meetings to learn skills which will help them in a variety of wellness areas such as physical exercises and diet. Attendance in these sessions will be encouraged but not mandatory, and attendance will be recorded. Fidelity with these interventions will be captured using diet and physical activity questionnaires at RCT start, midpoint and end, and end of open label phase.

Locations

Country Name City State
Canada Centre for Addiction and Mental Health Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
Centre for Addiction and Mental Health

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Individual's percentage change in body weight Percentage change in body weight measured in percentage change of pounds (lbs) Weeks 0, 4, 8, 12, 16, 10, 24
Secondary Proportion of participants who achieve body weight reduction =5%, and =10% in each arm Percentage change in body weight measured in percentage change of pounds (lbs), expressed as a percentage Week 0 and week 24
Secondary Between group (metformin vs placebo) absolute change in weight Absolute change in body weight between metformin and placebo groups measured in pounds (lbs). Calculated by the mean change in weight between the metformin and placebo groups. Week 24
Secondary Between group absolute change in waist circumference Absolute change in waist circumstance measured in centimetres (cm) between metformin and placebo groups. Calculated by the mean change in waist circumstance between the metformin and placebo groups. Week 24
Secondary Between group absolute change in BMI Absolute change in BMI between metformin and placebo groups. Calculated by the mean change in BMI between the metformin and placebo groups. Week 24
Secondary Change in whole body insulin sensitivity calculated with Matsuda Index With the results of the oral glucose tolerance test at Week 0 and Week 24, insulin sensitivity was calculated with the Matsuda index.
Insulin sensitivity was calculated with Matsuda index: [10,000 / vglucose minute 0 x insulin minute 0) (mean glucose (OGTT) x mean insulin OGTT)]. A higher result is better.
In the formula OGTT: oral glucose tolerance test.
Week 0 and Week 24
Secondary Change in beta-cell function, measured using the Insulin Secretion-Sensitivity Index-2 (ISSI-2) ISSI-2 is defined as the product of (i) insulin secretion measured by the ratio of the area-under-the-insulin-curve to the area-under-the-glucose curve and (ii) insulin sensitivity measured by the Matsuda index. Week 0 and Week 24
Secondary Proportion in each group converting to impaired glucose tolerance, prediabetes, or type 2 diabetes Measured through the change in HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) derived from the Oral Glucose Tolerance Test (OGTT). Week 0 and Week 24
Secondary Change in cardiovascular risk factors assessed by change in C-reactive protein Measured through the change in C-reactive protein (CRP) assessed at week 0 and week 24.
Healthy levels:
CRP: Less than 0.3 mg/dL
Week 0 and Week 24
Secondary Change in cardiovascular risk factor assessed by change in fasting lipids profile Change in fasting lipid profile (low-density lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL), and triglycerides) assessed at week 0 and week 24.
Healthy levels:
LDL: less than 100mg/dL HDL: 40mg/dL or higher Triglycerides: less than 150mg/dL
Week 0 and Week 24
Secondary Change in cardiovascular risk factor assessed by change in blood pressure Measured through the change in blood pressure (systolic/diastolic) assessed at week 0 and week 24. A blood pressure range of 110/70 to 120/80 is considered normal. Week 0 and Week 24
Secondary Change in visceral and liver fat content Change in visceral and liver fat content assessed via MRI scans at week 0 and week 24. Week 0 and Week 24
Secondary Medication Adherence Measured through returning of blister pill packs, and assessing number of pills taken. Week 0 to Week 24
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2